| Experiment ID | EXP00339 |
| Reference | Title: MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers. Author: Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H,Ochiai A. Journal: PLoS One. 2015 Feb 23;10(2):e0118220. doi: 10.1371/journal.pone.0118220.eCollection 2015. Abstract: It is difficult to detect pancreatic cancer or biliary-tract cancer at an earlystage using current diagnostic technology. Utilizing microRNA (miRNA) markersthat are stably present in peripheral blood, we aimed to identify pancreatic and biliary-tract cancers in patients. With 3D-Gene, a highly sensitive microarray,we examined comprehensive miRNA expression profiles in 571 serum samples obtainedfrom healthy patients, patients with pancreatic, biliary-tract, or otherdigestive cancers, and patients with non-malignant abnormalities in the pancreas or biliary tract. The samples were randomly divided into training and testcohorts, and candidate miRNA markers were independently evaluated. We found 81miRNAs for pancreatic cancer and 66 miRNAs for biliary-tract cancer that showedstatistically different expression compared with healthy controls. Among thosemarkers, 55 miRNAs were common in both the pancreatic and biliary-tract cancersamples. The previously reported miR-125a-3p was one of the common markers;however, it was also expressed in other types of digestive-tract cancers,suggesting that it is not specific to cancer types. In order to discriminate the pancreato-biliary cancers from all other clinical conditions including thehealthy controls, non-malignant abnormalities, and other types of cancers, wedeveloped a diagnostic index using expression profiles of the 10 most significantmiRNAs. A combination of eight miRNAs (miR-6075, miR-4294, miR-6880-5p,miR-6799-5p, miR-125a-3p, miR-4530, miR-6836-3p, and miR-4476) achieved asensitivity, specificity, accuracy and AUC of 80.3%, 97.6%, 91.6% and 0.953,respectively. In contrast, CA19-9 and CEA gave sensitivities of 65.6% and 40.0%, specificities of 92.9% and 88.6%, and accuracies of 82.1% and 71.8%,respectively, in the same test cohort. This diagnostic index identified 18/21operable pancreatic cancers and 38/48 operable biliary-tract cancers in theentire cohort. Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who couldbenefit from surgical intervention. PMID: 25706130 |
| Expressiion Profile | Description: MicroRNA markers for the diagnosis of pancreatic and biliary tract cancers Organism: Homo sapiens GEO ID: GSE59856 Platform: GPL18941 Number of samples: 571 |
| Design and Sample | Cancer Type: liver cancer Cancer SubType: N/D Cell Line: N/D Experimental Design: blood Case Sample: blood from liver cancer Control Sample: normal blood Num of Case: 52 Num of Control: 150 Quantification Software: limma Num of miRNAs: 2555 |
| Identification | Num of Up: 272 Num of Down: 411 |